Satellos Bioscience Reports Positive Phase Ia/b Results for SAT-3247 in Duchenne Muscular Dystrophy

Satellos Bioscience has released new Phase Ia/b data demonstrating that SAT-3247 was well tolerated and safe in adults aged 20–27 years with Duchenne muscular dystrophy (DMD), showing a desirable pharmacokinetic profile. Over 28 days, participants receiving SAT-3247 exhibited notable improvements in grip strength, with a 118.6% increase in the dominant hand and 97.9% in the non-dominant hand, effectively doubling strength from around 2kg to 4kg.

These gains were inconsistent with the natural disease course and correlated with elevated drug concentrations and baseline creatinine levels, suggesting increased muscle mass. Five adults participated in the trial and will now join an 11-month open-label follow-up study, which will also include males aged 16–25 years. The follow-up will assess long-term safety, tolerability, and muscle fat fraction. Satellos is also planning a Phase II placebo-controlled trial in ambulatory children with DMD.

13-10-2025